Transgene S.A. (0OCQ) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Transgen twenty twenty five Annual Results and Prospective for twenty twenty six Conference Call and Webcast. At this time, all participants are in listen only mode. After the speakers' presentation, there will be the question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Lucie Larguer. Please go ahead. Well, thank you, Nadia, and hello, everyone. So I'm Lucie Trifan, L'Officer Transgene, and I'm with Doctor. Alessandro Riva, our Chairman and CEO today. We will review the progress over 2025 and answer any questions you may have. Before I turn the call over to Alessandro, I'd like to remind everyone that today's discussion contains forward looking statements, which are subject to multiple risks and uncertainties. If you have followed the webcast online, you can, as Nadia said, submit your questions via the chat function on the platform or also dial in. So don't hesitate to let us know and make it as interactive as possible. With this, I now turn the call over to Alessandro. Thanks, Lucy, and good morning, good evening, good afternoon, everyone. So 2025 has been a year on meaningful clinical progress for Transgene. As you all know, we advanced our individualizing antigen therapeutic vaccine, INTD, TG4050, supported by compelling clinical and translational data in head and neck cancer that reinforce our confidence in its potential to prevent relapse in patients. I would say that there were three crucial moments this year that confirm our conviction that the MyVac platform can bring benefit to patients. First of all, our phase one data being presented already at ASCO in the same session as two phase three tria...